Fig. 3

Iluzanebart increases surface levels of CSF1R. A iPSC Derived Human Microglia (iMGL). Treatment of iMGLs with iluzanebart increased levels of soluble CSF1R levels after 24 h, compared to IgG control which had no effect (n = 3 independent experiments). B Representative image of population analysis of iMGL post treatment with iluzanebart show increases the population of CSF1R + CD45 + iMGL compared to IgG or untreated control after 24 h. C Representative histogram of iMGL shows an increase of surface CSF1R iMGL with iluzanebart. D Quantification of mean fluorescence intensity (MFI) demonstrates a TREM2-dependent increase in surface levels of CSF1R by iluzanebart. N = 7 independent experiments for wildtype, n = 5 independent experiments for TREM2 knockout iMGL. Significance was determined by 2-way ANOVA with Sidak’s multiple comparison’s test. * < 0.05